TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 168 filers reported holding TURNING POINT THERAPEUTICS I in Q3 2020. The put-call ratio across all filers is 1.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $4,333,000 | +190.8% | 57,586 | +3.8% | 0.01% | +250.0% |
| Q1 2022 | $1,490,000 | -48.4% | 55,502 | -8.3% | 0.00% | -33.3% |
| Q4 2021 | $2,886,000 | -26.4% | 60,505 | +2.5% | 0.00% | -40.0% |
| Q3 2021 | $3,922,000 | -20.7% | 59,034 | -6.9% | 0.01% | -16.7% |
| Q2 2021 | $4,945,000 | -7.2% | 63,376 | +12.6% | 0.01% | -14.3% |
| Q1 2021 | $5,326,000 | -22.6% | 56,301 | -0.3% | 0.01% | -30.0% |
| Q4 2020 | $6,881,000 | +52.4% | 56,471 | +9.3% | 0.01% | +42.9% |
| Q3 2020 | $4,514,000 | +65.6% | 51,676 | +22.4% | 0.01% | +40.0% |
| Q2 2020 | $2,726,000 | +45.9% | 42,207 | +0.9% | 0.01% | +25.0% |
| Q1 2020 | $1,868,000 | -29.1% | 41,828 | -1.1% | 0.00% | 0.0% |
| Q4 2019 | $2,635,000 | +586.2% | 42,300 | +313.7% | 0.00% | +300.0% |
| Q3 2019 | $384,000 | -7.7% | 10,225 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $416,000 | – | 10,225 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 2,392,297 | $291,501,000 | 6.94% |
| Burrage Capital Management LLC | 72,484 | $8,832,000 | 6.73% |
| MPM BioImpact LLC | 617,372 | $75,226,000 | 6.50% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 113,541 | $13,816,000 | 3.77% |
| Orbimed Advisors | 2,745,327 | $334,518,000 | 2.93% |
| SECTORAL ASSET MANAGEMENT INC | 257,379 | $31,362,000 | 2.21% |
| Parkman Healthcare Partners LLC | 59,377 | $7,235,000 | 1.85% |
| Nicholas Investment Partners, LP | 183,676 | $22,381,000 | 1.73% |
| EMERALD ADVISERS, LLC | 357,038 | $43,505,000 | 1.44% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 336,173 | $40,963,000 | 1.42% |